Avapritinib is another newer multikinase inhibitor with highly selective and potent activity against mutated c-kit and platelet-derived growth factor receptor A mutants, and was approved based on the results of two multicenter, open-label clinical trials (EXPLORER and PATHFINDER) for the treatment of advanced SM. Here, KIT is linked to systemic mastocytosis.